Eupraxia Achieves >90% Inflammation, >83% Fibrosis Improvement at Top Dose
RESOLVE trial EoEHSS sub scores for inflammation improved across all cohorts at 12 and 36 weeks, with the highest dose (20×8mg) yielding over 90% reductions in inflammation grade and stage and over 83% improvements in fibrosis. Architectural sub scores also improved across most cohorts at both time points.
1. Overview of RESOLVE Phase 1b/2a Trial
Eupraxia initiated a multicenter, open-label, dose-escalation RESOLVE trial evaluating EP-104GI in adults with active eosinophilic esophagitis. Patients received single-dose esophageal wall injections ranging from 4×1mg to 20×8mg across nine cohorts, with follow-up through 24 weeks for cohorts 1-4 and 52 weeks for cohorts 5-9.
2. EoEHSS Sub Score Improvements
The EoE Histology Scoring System (EoEHSS) sub scores measure inflammation (grade and stage) and tissue architecture/fibrosis (grade and stage) across eight features. At week 12 and week 36, all cohorts showed inflammation score improvements, while most cohorts demonstrated architectural score gains.
3. Highest Dose Cohort Results
Cohort 9 (20×8mg) achieved the greatest benefit, exceeding 90% improvement in both inflammation grade and stage and over 83% improvement in fibrosis grade and stage at both 12 and 36 weeks.
4. Next Steps and Phase 2b Planning
Eupraxia plans to disclose additional Phase 1b/2a data in the coming months and is recruiting its randomized Phase 2b study at 120mg and 160mg doses. Top-line Phase 2b results are expected in Q4 2026.